Susquehanna International Group, LLP Assembly Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$1.7 - $20.52 $31,620 - $381,672	-18,600 Reduced 46.38%	21,500 $35,000
Q2 2022 Aug 15, 2022	BUY	$1.35 - $2.29 $37,665 - $63,891	27,900 Added 228.69%	40,100 $84,000
Q4 2021 Feb 14, 2022	SELL	$2.13 - $3.46 $13,845 - $22,490	-6,500 Reduced 34.76%	12,200 $28,000
Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $17,898 - $22,230	-5,700 Reduced 23.36%	18,700 $65,000
Q1 2021 May 17, 2021	BUY	$4.33 - $6.63 $51,960 - $79,560	12,000 Added 96.77%	24,400 $112,000
Q2 2020 Aug 14, 2020	SELL	$14.57 - $23.96 $651,279 - $1.07 Million	-44,700 Reduced 78.28%	12,400 $289,000
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $154,050 - $318,450	-15,000 Reduced 20.8%	57,100 $847,000
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $506,615 - $1.44 Million	60,600 Added 526.96%	72,100 $1.48 Million
Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $1.81 Million - $2.91 Million	-140,100 Reduced 92.41%	11,500 $155,000
Q1 2019 May 15, 2019	BUY	$17.7 - $24.93 $2.53 Million - $3.56 Million	142,700 Added 1603.37%	151,600 $2.99 Million
Q3 2018 Nov 14, 2018	SELL	$34.41 - $44.23 $48,173 - $61,921	-1,400 Reduced 13.59%	8,900 $331,000
Q2 2018 Aug 14, 2018	SELL	$39.21 - $50.29 $7.59 Million - $9.74 Million	-193,700 Reduced 94.95%	10,300 $404,000
Q1 2018 May 15, 2018	BUY	$41.7 - $64.16 $5.48 Million - $8.44 Million	131,500 Added 181.38%	204,000 $10 Million
Q4 2017 Feb 14, 2018	BUY	$28.58 - $49.91 $2.07 Million - $3.62 Million	72,500	72,500 $3.28 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $765M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.